NASDAQ · RLMD
Healthcare · Biotechnology
$4.22
Down-$0.22 (-4.95%)
Updated Sep 17, 2026, 4:25 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RLMD closed at $4.22 after 20 trading sessions, down 12.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $4.45 | $4.5724 | $4.205 | $4.22 | 824.38K |
| Sep 15, 2026 | $4.44 | $4.495 | $4.30 | $4.44 | 2M |
| Sep 14, 2026 | $4.52 | $4.56 | $4.42 | $4.44 | 1.26M |
| Sep 11, 2026 | $4.60 | $4.65 | $4.295 | $4.52 | 2.63M |
| Sep 10, 2026 | $4.25 | $4.25 | $4.00 | $4.07 | 2.81M |
| Sep 9, 2026 | $4.24 | $4.28 | $4.09 | $4.09 | 1.59M |
| Sep 8, 2026 | $4.40 | $4.425 | $4.13 | $4.25 | 1.7M |
| Sep 4, 2026 | $4.35 | $4.44 | $4.32 | $4.43 | 675.56K |
| Sep 3, 2026 | $4.55 | $4.58 | $4.33 | $4.37 | 847.51K |
| Sep 2, 2026 | $4.54 | $4.5932 | $4.365 | $4.54 | 1.42M |
| Sep 1, 2026 | $4.31 | $4.51 | $4.31 | $4.46 | 944.06K |
| Aug 31, 2026 | $4.31 | $4.395 | $4.285 | $4.36 | 628.24K |
| Aug 28, 2026 | $4.51 | $4.53 | $4.32 | $4.33 | 678.36K |
| Aug 27, 2026 | $4.53 | $4.58 | $4.485 | $4.52 | 496.49K |
| Aug 26, 2026 | $4.57 | $4.60 | $4.46 | $4.55 | 476.69K |
| Aug 25, 2026 | $4.63 | $4.725 | $4.57 | $4.59 | 1.03M |
| Aug 24, 2026 | $4.64 | $4.64 | $4.375 | $4.58 | 935.75K |
| Aug 21, 2026 | $4.68 | $4.76 | $4.54 | $4.63 | 985.17K |
| Aug 20, 2026 | $4.74 | $4.79 | $4.55 | $4.64 | 1.03M |
| Aug 19, 2026 | $4.94 | $4.98 | $4.79 | $4.83 | 595.94K |
The latest Smart Investors Daily articles mentioning RLMD.
RLMD research
Company profile and research snapshot.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 24, 2026 | Piper Sandler | Overweight | — |
| Mar 20, 2026 | Mizuho | Outperform | — |
| Mar 2, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jan 23, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
Relmada Therapeutics is rated Hold as NVD-01 IND slips to 2026 despite strong NMIBC data; cash runway to 2029. Click here to read my latest analysis on RLMD stock.
Yahoo · Sep 14, 2026
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
Benzinga · Sep 11, 2026
Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose
Yahoo · Sep 1, 2026
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026. Wells Fargo 21st Annual Healthcare Conference DetailsFormat: One-o
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RLMD.
